The global transdermal patch market, valued at $7.8 billion in 2023, is projected to reach nearly $10.95 billion by 2030, with pain patches expected to grow from $4.8 billion in 2021 to $7.3 billion by 2031. This growth is driven by the need for safer alternatives to traditional opioid use and the convenience of transdermal drug delivery. Among the companies leading this shift are Nutriband Inc., Collegium Pharmaceutical, Inc., Assertio Holdings, Inc., and Aquestive Therapeutics, Inc., each contributing innovative solutions to pain therapy and drug delivery.
Nutriband Inc. is making strides with its AVERSA Fentanyl, a transdermal patch designed to deter abuse, misuse, and accidental exposure, potentially reaching peak annual US sales of between 80 million and 200 million dollars. Collegium Pharmaceutical, Inc. reported a 23 percent year-over-year increase in net revenue, driven by its pain and ADHD medications. Assertio Holdings, Inc. is focusing on high-potential assets and business development after settling multiple lawsuits, while Aquestive Therapeutics, Inc. is advancing its innovative, non-invasive epinephrine treatment for severe allergic reactions.
These companies exemplify the potential of small-cap biopharma firms to address critical healthcare challenges through innovation, offering investors opportunities in a rapidly growing market segment. Their progress underscores the importance of transdermal drug delivery in improving patient care and reducing the risks associated with traditional pain management methods.
